Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Date publication

mars 2007

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr RIOS Maria

Tous les auteurs :
Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/17369574

Résumé

Imatinib is the standard treatment of advanced GI stromal tumors (GISTs). It is not known whether imatinib may be stopped in patients in whom disease is controlled.

Mots clés

Adult, Aged, Aged, 80 and over, Antineoplastic Agents, administration & dosage, Benzamides, Disease-Free Survival, Drug Administration Schedule, Female, Follow-Up Studies, France, Gastrointestinal Stromal Tumors, drug therapy, Humans, Imatinib Mesylate, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Piperazines, administration & dosage, Practice Guidelines as Topic, Prospective Studies, Protein Kinase Inhibitors, administration & dosage, Pyrimidines, administration & dosage, Quality of Life, Surveys and Questionnaires, Treatment Outcome

Référence

J. Clin. Oncol.. 2007 Mar;25(9):1107-13